Bromopride

Bromopride
	File:Bromopride.svg
Clinical data
Routes of; administration	Oral, IM, IV
ATC code	A03FA04 (WHO) ;
Legal status
Legal status	Red Label (BR);
Pharmacokinetic data
Bioavailability	50 to 75% (oral); 78% (intramuscular)
Protein binding	40%
Metabolism	Hepatic
Elimination half-life	4 to 5 hours
Excretion	Renal, 10 to 14% unchanged
Identifiers
	IUPAC name 4-amino-5-bromo-N-(2-diethylaminoethyl)-; 2-methoxybenzamide;
CAS Number	4093-35-0;
PubChem CID	2446;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C14H22BrN3O2
Molar mass	344.248 g/mol

Bromopride (INN) is a dopamine antagonist with prokinetic properties widely used as an antiemetic, closely related to metoclopramide. It is not available in the United States.

Bromopride appears to be safe and effective for use in pregnancy.^[1]

Indications

Bromopride is indicated in the treatment of nausea and vomiting, including postoperative nausea and vomiting (PONV); gastroesophageal reflux disease (GERD/GORD); and as preparation for endoscopy and radiographic studies of the gastrointestinal tract. The manufacturer also claims it is valuable in, among other indications, hiccups and gastrointestinal adverse effects of radiation therapy.

Adverse effects

Bromopride is generally well tolerated; the most common adverse effects of its use are somnolence and fatigue. Bromopride may rarely cause extrapyramidal symptoms and, as metoclopramide, may increase prolactin levels.^[2]

Chemistry

Bromopride is a substituted benzamide, closely related to metoclopramide.^[3] It is identical to metoclopramide except for the presence of a bromine atom where metoclopramide has a chlorine substituent.

Availability

Bromopride is not available in the United States or the United Kingdom. It is marketed in Brazil by Sanofi-Synthélabo under the trade name Digesan and as a generic drug.

References

↑ Araújo JR (1981). "Evaluation of bromopride in nausea and vomiting of pregnancy". J Bras Ginecol (in Portuguese). 91 (4): 283–5.
↑ "Bula do Profissional de Saúde: Bromoprida". Bulário Eletrônico da Anvisa (in Portuguese). Brazilian National Health Surveillance Agency. April 11 2006. Retrieved 2007-07-23. Check date values in: |date= (help)
↑ Brodie RR, Chasseaud LF, Darragh A, Lambe RF, Rooney L, Taylor T (1986). "Pharmacokinetics and bioavailability of the anti-emetic agent bromopride". Biopharm Drug Dispos. 7 (3): 215–22. doi:10.1002/bdd.2510070302. PMID 3730521.

Template:WikiDoc Sources

[1] Araújo JR (1981). "Evaluation of bromopride in nausea and vomiting of pregnancy". J Bras Ginecol (in Portuguese). 91 (4): 283–5.

[2] "Bula do Profissional de Saúde: Bromoprida". Bulário Eletrônico da Anvisa (in Portuguese). Brazilian National Health Surveillance Agency. April 11 2006. Retrieved 2007-07-23. Check date values in: |date= (help)

[3] Brodie RR, Chasseaud LF, Darragh A, Lambe RF, Rooney L, Taylor T (1986). "Pharmacokinetics and bioavailability of the anti-emetic agent bromopride". Biopharm Drug Dispos. 7 (3): 215–22. doi:10.1002/bdd.2510070302. PMID 3730521.

[1]

[2]

[3]

Clinical data
File:Bromopride.svg
Routes of administration	Oral, IM, IV
ATC code	A03FA04 (WHO)
Legal status
Legal status	Red Label (BR)
Pharmacokinetic data
Bioavailability	50 to 75% (oral) 78% (intramuscular)
Protein binding	40%
Metabolism	Hepatic
Elimination half-life	4 to 5 hours
Excretion	Renal, 10 to 14% unchanged
Identifiers
IUPAC name 4-amino-5-bromo-N-(2-diethylaminoethyl)- 2-methoxybenzamide
CAS Number	4093-35-0
PubChem CID	2446
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₄H₂₂BrN₃O₂
Molar mass	344.248 g/mol